Idazoxan

Idazoxan
Clinical data
Routes of
administration
Oral
ATC code none
Legal status
Legal status
  • Uncontrolled
Identifiers
CAS Number 79944-58-4 YesY
PubChem (CID) 54459
ChemSpider 49184 N
UNII Y310PA316B N
ChEMBL CHEMBL10316 N
Chemical and physical data
Formula C11H12N2O2
Molar mass 204.225 g/mol
3D model (Jmol) Interactive image
Chirality Racemic mixture
 NYesY (what is this?)  (verify)

Idazoxan (INN) is a drug which is used in scientific research. It acts as both a selective α2 adrenergic receptor antagonist, and an antagonist for the imidazoline receptor.[1][2] Idazoxan has been under investigation as an antidepressant, but it did not reach the market as such. More recently, it is under investigation as an adjunctive treatment in schizophrenia. Due to its alpha-2 receptor antagonism it is capable of enhancing therapeutic effects of antipsychotics, possibly by enhancing dopamine neurotransmission in the prefrontal cortex of the brain, a brain area thought to be involved in the pathogenesis of schizophrenia.

See also

References

  1. Bousquet, P; Bruban, V; Schann, S; Greney, H; Ehrhardt, JD; Dontenwill, M; Feldman, J (1999). "Participation of imidazoline receptors and alpha(2-)-adrenoceptors in the central hypotensive effects of imidazoline-like drugs". Annals of the New York Academy of Sciences. 881: 272–8. doi:10.1111/j.1749-6632.1999.tb09369.x. PMID 10415925.
  2. Clarke, RW; Harris, J (2002). "RX 821002 as a tool for physiological investigation of alpha(2)-adrenoceptors". CNS Drug Reviews. 8 (2): 177–92. doi:10.1111/j.1527-3458.2002.tb00222.x. PMID 12177687.


This article is issued from Wikipedia - version of the 5/31/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.